Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.